Pilgrim Partners Asia’s Genmab GMAB Stock Holding History

Pilgrim Partners Asia’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-18,800	Closed	-$392K	–	140
2024 Q4	$392K	Buy	+18,800	New	+$413K	0.34%	33

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Pilgrim Partners Asia's GMAB Position: Q1 2025 in Review

Pilgrim Partners Asia sold out of Genmab (GMAB) in Q1 2025, closing a stake of 18,800 shares — an estimated $392K sold.

Pilgrim Partners Asia first reported a position in GMAB in Q4 2024 and held it in 1 quarter. The position peaked at $392K in Q4 2024. 219 funds tracked by Wall St. Rank hold GMAB as of Q1 2025.

Pilgrim Partners Asia reported no remaining Genmab position as of Q1 2025 after selling out during the quarter.
Pilgrim Partners Asia sold 18,800 Genmab shares in Q1 2025, an estimated $392K.
Pilgrim Partners Asia first reported a position in Genmab in Q4 2024 and held it in 1 quarter.
Pilgrim Partners Asia's Genmab position peaked at $392K in Q4 2024.
219 funds tracked by Wall St. Rank held Genmab as of Q1 2025.

Based on Pilgrim Partners Asia's 13F filing for Q1 2025, filed 14 May 2025.